D. B. Johnson and J. A. Sosman, Curr Treat Options Oncol, vol.2013, issue.14, pp.280-292

H. Davies, G. R. Bignell, and C. Cox, Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.949-954, 2002.
DOI : 10.1016/S0960-9822(97)70094-0

H. T. Arkenau, R. Kefford, and G. Long, Targeting BRAF for patients with melanoma, British Journal of Cancer, vol.365, issue.3, pp.392-398, 2011.
DOI : 10.1016/S0092-8674(04)00215-6

D. Capper, A. S. Berghoff, and M. Magerle, Acta Neuropathol, vol.2012, issue.123, pp.223-233

O. Koperek, C. Kornauth, and D. Capper, Am J Surg Pathol, vol.2012, issue.36, pp.844-850

K. J. Busam, C. Hedvat, and M. Pulitzer, Am J Surg Pathol, vol.2013, issue.37, pp.413-420

E. Colomba, Z. Helias-rodzewicz, V. Deimling, and A. , J Mol Diagn, vol.2013, issue.15, pp.94-100

G. V. Long, J. S. Wilmott, and D. Capper, Am J Surg Pathol, vol.2013, issue.37, pp.61-65

J. S. Wilmott, A. M. Menzies, and L. Haydu, Br J Cancer, vol.2013, issue.108, pp.924-931

H. Tsao, X. Zhang, and K. Fowlkes, Cancer Res, vol.60, pp.1800-1804, 2000.

J. A. Puig-butille, C. Badenas, and Z. Ogbah, Exp Dermatol, vol.2012, issue.22, pp.148-150

J. A. Curtin, K. Busam, and D. Pinkel, Somatic Activation of KIT in Distinct Subtypes of Melanoma, Journal of Clinical Oncology, vol.24, issue.26, pp.4340-4346, 2006.
DOI : 10.1200/JCO.2006.06.2984

P. B. Chapman, A. Hauschild, and C. Robert, Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2516, 2011.
DOI : 10.1056/NEJMoa1103782

K. T. Flaherty, J. R. Infante, and A. Daud, N Engl J Med, vol.2012, issue.367, pp.1694-1703

K. T. Flaherty, C. Robert, and P. Hersey, N Engl J Med, vol.2012, issue.367, pp.107-114

F. S. Hodi, C. L. Corless, and A. Giobbie-hurder, J Clin Oncol, vol.2013, issue.31, pp.3182-3190

O. Kabbarah, C. Nogueira, and B. Feng, PLoS One, issue.5, p.10770, 2010.

H. 18-rizos, A. M. Menzies, and G. Pupo, Clin Cancer Res, vol.2014, issue.20, pp.1965-1977

D. B. Solit and N. Rosen, Resistance to BRAF Inhibition in Melanomas, New England Journal of Medicine, vol.364, issue.8, pp.772-774, 2011.
DOI : 10.1056/NEJMcibr1013704

N. Gervois, F. Heuze, and E. Diez, Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: Cytotoxic activity and T cell receptor gene rearrangements, European Journal of Immunology, vol.1, issue.4, pp.825-831, 1990.
DOI : 10.1002/eji.1830200417

M. C. Pandolfino, S. Saiagh, and A. Knol, Comparison of three culture media for the establishment of melanoma cell lines, Cytotechnology, vol.164, issue.5, pp.403-412, 2010.
DOI : 10.4049/jimmunol.164.1.495

R. Halaban, S. Ghosh, and P. Duray, Human Melanocytes Cultured from Nevi and Melanomas, Journal of Investigative Dermatology, vol.87, issue.1, pp.95-101, 1986.
DOI : 10.1111/1523-1747.ep12523594

A. Jarry, D. Masson, and E. Cassagnau, Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E, Molecular and Cellular Probes, vol.18, issue.5, pp.349-352, 2004.
DOI : 10.1016/j.mcp.2004.05.004

M. Momose, H. Ota, and M. Hayama, Re-evaluation of melanin bleaching using warm diluted hydrogen peroxide for histopathological analysis, Pathology International, vol.20, issue.6, pp.345-350, 2011.
DOI : 10.1097/00000372-199808000-00006

M. Saint-jean, G. Quereux, and J. Nguyen, J Invest Dermatol, vol.2013, issue.134, pp.1468-1470

M. Colombino, M. Capone, and A. Lissia, J Clin Oncol, vol.2012, issue.30, pp.2522-2529

M. 27-yancovitz, A. Litterman, and J. Yoon, PLoS One, vol.2012, pp.7-29336

S. Ugurel, R. K. Thirumaran, and S. Bloethner, PLoS One, issue.2, p.236, 2007.